Intracerebral versus subcutaneous immunization with allogeneic fibroblasts genetically engineered to secrete interleukin-2 in the treatment of central nervous system glioma and melanoma

Neurosurgery

Volumn 41, Issue 4, 1997, Pages 898-907

  Glick, Roberta P ^a,b,c   Lichtor, Terry ^a,c   Mogharbel, Asma ^a   Taylor, Catherine A ^a   Cohen, Edward P ^b  

^a Jr Hospital of Cook County   (United States)

^b UNIVERSITY OF ILLINOIS   (United States)

^c LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Fibroblasts; Gene therapy; Glioma; Immunotherapy; Interleukin; Melanoma

Indexed keywords

INTERLEUKIN 2;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BRAIN; CANCER IMMUNOTHERAPY; FIBROBLAST; GENE THERAPY; GLIOMA; HISTOPATHOLOGY; IMMUNOCYTOTOXICITY; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; SUBCUTANEOUS TISSUE; SURVIVAL;

ANIMALS; BRAIN; BRAIN NEOPLASMS; FEMALE; FIBROBLASTS; GENE THERAPY; GENETIC ENGINEERING; GLIOMA; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INJECTIONS; INJECTIONS, SUBCUTANEOUS; INTERLEUKIN-2; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; NEOPLASM PROTEINS; NEOPLASM TRANSPLANTATION; TUMOR CELLS, CULTURED;

EID: 0030773890     PISSN: 0148396X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006123-199710000-00025     Document Type: Article

References (28)

1. Banks WA, Kastin AJ, Broadwell RD: Passage of cytokines across the blood-brain barrier. Neuroimmunomodulation 2:241-248, 1995.
2. Barba D, Saris SC, Holder C, Rosenberg SA, Oldfield EH: Intratumoral LAK cell and interleukin-2 therapy of human gliomas. J Neurosurg 70:175-182, 1989.
3. Colbere-Gerain F, Horodniceanu F, Kourilsky P, Garapin A: A new dominant hybrid selective marker for eukaryotic cells. J Mol Biol 150:1-14, 1981.
4. Fakhrai I, Dorigo O, Shawler DL, Lin H, Mercola D, Black KL, Royston I, Sobol RE: Eradication of established intracranial rat gliomas by TGF-β antisense gene therapy. Proc Natl Acad Sci USA 93:2909-2914, 1996.
5. Fearon ER, Itaya T, Hunt B, Vogelstein B, Frost P: Induction in a murine tumor of immunogenic tumor variants by transfection with a foreign gene. Cancer Res 48:2975-2980, 1988.
6. Gillis S, Ferm MM, Ou W, Smith KA: T cell growth factor: Parameters for production and quantitative microassay for activity. J Immunol 120:2027-2032, 1978.
7. Glick RP, Lichtor T, Kim TS, Ilangovan S, Cohen EP: Fibroblasts genetically engineered to secrete cytokines suppress tumor growth and induce antitumor immunity to a murine glioma in vivo. Neurosurgery 36:548-555, 1995.
8. Hui KM, Sim TF, Foo TT, Oei A-A: Tumor rejection mediated by transfection with allogeneic class I histocompatibility gene. J Immunol 143:3835-3843, 1989.
9. Kim TS, Cohen EP: Immunization of mice with allogeneic fibroblasts genetically modified for interleukin-2-secretion and expression of melanoma-associated antigens stimulates predetermined classes of anti-melanoma effector cells. J Immunother 16:24-35, 1994.
10. Kim TS, Cohen EP: Interleukin-2-secreting mouse fibroblasts transfected with genomic DNA from murine melanoma cells prolong the survival of mice with melanoma. Cancer Res 54: 2531-2535, 1994.
11. Kim TS, Russell SJ, Collins MKL, Cohen EP: Immunity to B16 melanoma in mice immunized with IL-2-secreting allogeneic mouse fibroblasts expressing melanoma-associated antigens. Int J Cancer 51:283-289, 1992.
12. Kim TS, Russell SJ, Collins MKL, Cohen EP: Immunization with interleukin-2-secreting allogeneic mouse fibroblasts expressing melanoma-associated antigens prolongs the survival of tumor-bearing mice with melanoma. Int J Cancer 55:865-872, 1993.
13. Kim YS, Slomski R, Cohen EP: Immunity to melanoma in mice immunized with transfected allogeneic mouse fibroblasts expressing melanoma-associated antigens. Cancer Immunol Immunother 34:163-168, 1991.
14. Lichtor T, Glick RP, Kim TS, Hand R, Cohen EP: Prolonged survival of mice with glioma injected intracerebrally with double cytokine-secreting cells. J Neurosurg 83:1038-1044, 1995.
15. Mahaley MS, Mettlin C, Natarajan N, Laws ER Jr, Peace BB: National survey on patients of care for brain-tumor patients. J Neurosurg 71:826-836, 1989.
16. Markowitz D, Goff S, Bank A: Construction and use of a safe and efficient amphotropic packaging cell line. Virology 167:400-406, 1988.
17. Merchant RE, Ellison MD, Young HF: Immunotherapy for malignant glioma using human recombinant interleukin-2 and activated autologous lymphocytes: A review of pre-clinical and clinical investigations. J Neurooncol 8:173-188, 1990.
18. Merchant RE, McVicar DW, Merchant LH, Young HF: Treatment of recurrent malignant glioma by repeated intracerebral injections of human recombinant interleukin-2 alone or in combination with systemic interferon-α: Results of a phase I clinical trial. J Neurooncol 12:75-83, 1992.
19. Ostrand-Rosenberg S, Thakur A, Clements V: Rejection of mouse sarcoma cells after transfection of MHC class II genes. J Immunol 144:4068-4071, 1990.
20. Ram Z, Walbridge S, Heiss JD, Culver KW, Blaese RM, Oldfield EH: In vivo transfer of the human interleukin-2 gene: Negative tumoricidal results in experimental brain tumors. J Neurosurg 80:535-540, 1994.
21. Robinson WA, Jobe K, Stevens R: Central nervous system metastases in malignant melanoma. Cancer Treat Res 35:155-163, 1987.
22. Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Lineham WM, Robertson CN, Lee RE, Rubin JT, Seipp CA, Simpson CG, White DEA: A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high dose of interleukin-2 alone. N Engl J Med 316:889-905, 1987.
23. Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Tov ST, Simon P, Lotze MT, Yang JC, Seipp CA, Simpson CG, Carter C, Bock S, Schwartzentruber D, Wei JP, White DE: Use of tumor infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. N Engl J Med 319:1676-1680, 1988.
24. Saris SC, Spiess P, Lieberman DM, Lin S, Walbridge S, Oldfield EH: Treatment of murine primary brain tumors with systemic interleukin-2 and tumor-infiltrating lymphocytes. J Neurosurg 76:513-519, 1992.
25. Tjuvajev J, Gansbacher B, Desai R, Beattie B, Kaplitt M, Matei C, Koutcher J, Gilboa E, Blasberg R: RG-2 glioma growth attenuation and severe brain edema caused by local production of interleukin-2 and interferon-γ. Cancer Res 55:1902-1910, 1995.
26. Watts RG, Wright JL, Atkinson LL, Merchant RE: Histopathological and blood-brain barrier changes in rats induced by intracerebral injection of human recombinant interleukin 2. Neurosurgery 25:202-208, 1989.
27. Yamada G, Kitamura Y, Sonada H, Harada H, Taki S, Mulligan RC, Osawa H, Diamansteain T, Yokoyama S, Taniguchi T: Retroviral expression of the human IL-2 gene in a murine T cell line results in cell growth autonomy and tumorigenicity. EMBO J 6:2705-2709, 1987.
28. Zhang RD, Price JE, Fujimaki T, Bucana CD, Fidler IJ: Differential permeability of the blood brain barrier in experimental brain metastases produced by human neoplasms implanted into nude mice. Am J Pathol 141:1115-1124, 1992.